轻松健康集团通过港交所聆讯：上半年营收同比增85%，AI技术成增长重要引擎

Core Viewpoint - The company, Qingsong Health Group, has developed a proprietary AI technology stack, AIcare, which serves as the core support for its platform and is preparing for an IPO on the Hong Kong Stock Exchange [3][4]. Group 1: Business Overview - Founded in 2014, Qingsong Health Group operates as a one-stop digital health and insurance service platform, with two main business pillars: "Digital Comprehensive Health Services" and "Digital Comprehensive Insurance Services" [3]. - According to a report by Sullivan, Qingsong Health Group ranks 10th in China's digital comprehensive health services and health insurance market based on projected 2024 revenue, and 7th in the digital health services market [3]. - As of June 30, 2025, the platform has 168 million registered users and approximately 59.7 million followers across WeChat, mini-programs, and corporate WeChat accounts [3]. Group 2: User Demographics and Growth Potential - As of June 30, 2025, about 60.4% of users are aged between 20 and 45 years, indicating a younger user base that is likely to increase health solution spending as they experience life events such as marriage and childbirth [4]. - This demographic trend provides significant upselling and cross-selling opportunities for Qingsong Health Group to maximize customer lifetime value [4]. - The younger users also invite family members to purchase health and insurance services, further enhancing growth potential [4]. Group 3: Technological Advancements - AI technology is a crucial growth engine for Qingsong Health Group, with 43.3% of its employees dedicated to IT research and development [4]. - The company has registered 58 invention patents and 39 software copyrights related to its technological capabilities as of June 30, 2025 [4]. - The Galaxy AI marketing platform has generated nearly 12.9 million business leads through personalized marketing activities [5]. Group 4: Financial Performance - Qingsong Health Group's revenue from 2022 to 2024 is projected to be 394 million, 490 million, and 945 million yuan, respectively, with a compound annual growth rate of 54.9% [5]. - In the first half of this year, the company's revenue increased by 84.7% year-on-year to 656 million yuan, while the adjusted net profit for the same period was 51.18 million yuan, reflecting an 11.3% year-on-year growth [5]. Group 5: IPO Fund Utilization - The net proceeds from the IPO will primarily be used to enhance brand awareness, increase user engagement, strengthen partnerships, conduct medical and real-world research, improve AI and big data capabilities, expand into more regions and overseas markets, and for general corporate purposes [6].